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Abstract
The infection of hepatitis B virus (HBV) is closely associated with the development of hepatocellular carcinoma
(HCC), in which HBV X protein (HBx) plays crucial roles. MicroRNAs are involved in diverse biologic functions and
in carcinogenesis by regulating gene expression. In the present study, we aim to investigate the underlying mecha-
nism by which HBx enhances hepatocarcinogenesis. We found that miR-205 was downregulated in 33 clinical HCC
tissues in comparison with adjacent noncancerous hepatic tissues. The expression levels of miR-205 were inversely
correlated with those of HBx in abovementioned tissues. Then, we demonstrated that HBx was able to suppress
miR-205 expression in hepatoma and liver cells. We validated that miR-205 directly targeted HBx mRNA. Ectopic
expression ofmiR-205 downregulated HBx, whereas depletion of endogenousmiR-205 upregulated HBx in hepatoma
cells. Notably, our data revealed that HBx downregulated miR-205 through inducing hypermethylation of miR-205
promoter in the cells. In terms of function, the forced miR-205 expression remarkably inhibited the HBx-enhanced
proliferation of hepatoma cells in vitro and in vivo, suggesting that miR-205 is a potential tumor-suppressive gene
in HCC. HBx-transgenic mice showed that miR-205 was downregulated in the liver. Importantly, HBx was able
to abrogate the effect of miR-205 on tumor suppression in carcinogenesis. Therefore, we conclude that HBx is
able to inhibit tumor suppressor miR-205 to enhance hepatocarcinogenesis through inducing hypermethylation of
miR-205 promoter during their interaction. Therapeutically, miR-205 may be useful in the treatment of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-
related death in the world with annual death rate accounting for
700,000 [1,2]. Hepatitis B virus (HBV) is a hepatotropic noncyto-
pathic DNA virus, which is a major cause of chronic liver disease and
can lead to viral hepatitis, cirrhosis, and HCC [3–5]. As a multi-
functional transactivator protein [6], the HBV X protein (HBx) plays
crucial roles in HBV-associated HCC [5,7–9].
MicroRNAs (miRNAs), roughly 22-nucleotide noncoding RNAs,
posttranscriptionally modulate gene expression through repression
of translation and degradation of complementary target mRNAs [10],
which are being increasingly recognized as a crucial determinant of
tumor development and progression [11]. Several recent studies indi-
cate that miRNAs play critical roles in variety of biologic processes,
including development, differentiation, cellular proliferation, apoptosis,
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metabolism, and immunity [11–13]. Growing evidence supports a role
of miRNAs as both targets and effectors in aberrant mechanisms of
DNA hypermethylation [14]. It has been reported that some miRNAs
are inactivated in human tumors by aberrant hypermethylation of
cytosine-phosphate-guanosine (CpG) islands encompassing miRNA
genes [15,16]. Recent studies demonstrate that the expression levels of
miR-205, targeting E2-promoter binding factor 1 (E2F1), human epi-
dermal growth factor receptor 3 (HER3), and protein kinase Cɛ, are sig-
nificantly downregulated in melanoma and breast and prostate cancers
[17–19]. However, the role of miR-205 in HCC is poorly understood.
In the present study, we investigated the effect of HBx on miR-205
on hepatoma cells. Our results imply that miR-205 is a potential
tumor suppressor gene. We show that HBx is able to downregulate
the miR-205 during their interaction, resulting in the development
of HCC. Our finding provides new insights into the mechanism of
HBx-induced hepatocarcinogenesis.
Materials and Methods
Patient Samples and HBx-Transgenic Mice
Thirty-three HCC tissues and their corresponding nearby non-
tumorous liver tissues used in this study were obtained from Tianjin
First Center Hospital (Tianjin, PR China) after surgical resection.
Written consents approving the use of their tissues for research pur-
poses were obtained from patients. The study protocol was approved
by the Institute Research Ethics Committee at the Nankai University
(Tianjin, PR China). HBx-transgenic mice were obtained fromGenetic
Laboratory of Development and Diseases, Institute of Biotechnology
(Beijing, PR China) [20].
Cell Lines and Cell Culture
Hepatoma cell lines HepG2, HepG2-X (a stably HBx-transfected
hepatoma HepG2 cell line), and HepG2.2.15 (a hepatoma HepG2
cell line stably transfected with HBV genome) were maintained in
Dulbecco’s modified Eagle’s medium (Gibco, Grand Island, NY) [21].
The cell lines of LO2 (a human immortalized liver cell line), LO2-X
(a stably HBx-transfected LO2 cell line), and H7402-X (a stably HBx-
transfected hepatoma H7402 cell line) [21] were cultured in RPMI
Medium 1640 (Gibco) supplemented with 10% fetal calf serum,
100 U/ml penicillin, and 100 mg/ml streptomycin in 5% CO2 at 37°C.
DNA Constructs
The 5′-flanking region (nucleotides −4178 to −2751) of miR-205
was amplified by polymerase chain reaction (PCR) from the genomic
DNA of HepG2 using specific primers and was cloned into the up-
stream of the pGL3-Basic Vector (Promega, Madison, WI) through
KpnI and XhoI sites. The resulting plasmid was sequenced and
named pGL3-1428. The regions (−3429/−2751, −4178/−3416,
−3888/−3416, and −3888/−3588) of miR-205 were amplified by
PCR from the pGL3-1428 and were inserted into the pGL3-Basic
vector to generate pGL3-679, pGL3-763, pGL3-473, and pGL3-301,
respectively. All primers are listed in Table W1.
Plasmids, miRNAs, Small Interfering RNA, and
DNA Transfection
The cells were cultured in a 6-well or 24-well plate for 24 hours and
thenwere transfected with plasmid ormiRNA. All transfections were per-
formed using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol. The pSilencer-X (pSi-HBx)
produces small interfering RNAs (siRNAs) targeting HBx mRNA, and
pSilencer-control as negative control (NC) were used [22]. The plasmid
pCH-9/3091 containing the complete HBV genome has been de-
scribed previously [23]. The miR-205 mimics (miR-205), mimic
NC, miR-205 inhibitor (anti–miR-205), inhibitor NC, HBx siRNA
oligonucleotides [24], and NC siRNA were produced from RiboBio
(Guangzhou, PR China). A ∼460-bp fragment of HBx was cloned into
the pGL3-Control vector (Promega) downstream of the stop codon of
the luciferase gene to generate pGL3-HBx. pGL3-HBx-mut carried
a substitution of five nucleotides within the core seed sequence of
miR-205, which was carried out using overlapping extension PCR
[25]. The sequences were all listed in Table W1.
RNA Extraction and Quantitative Real-Time Reverse
Transcription–PCR
Total RNA was extracted from cells (mice or patient tissues) using
TRIzol reagent (Invitrogen). For mature miR-205 detection, 20 μg
of total RNA was polyadenylated by Poly(A) Polymerase (Ambion,
Austin, Texas) as described previously [26]. Reverse transcription was
performed using poly(A)-tailed total RNA and reverse transcription
primer. Quantitative real-time reverse transcription–PCR (qRT-PCR)
was performed by a Bio-Rad Laboratories (Berkeley, CA) sequence
detection system according to the manufacturer’s instructions using
double-stranded DNA SYBR GreenPremix Ex TaqTM II Kit (Takara
Bio, Tokyo, Japan). Relative transcriptional folds were calculated as
2−ΔΔ Ct [27]. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and U6 were used as internal control for normalization. All the primers
used are listed in Table W1.
Luciferase Reporter Gene Assay
Luciferase reporter gene assay was performed using the Dual-
Luciferase Reporter Assay System (Promega) according to the manufac-
turer’s instructions. Cells were transferred into 24-well plates at 3 ×
104 cells per well. After 24 hours, the cells were transiently cotrans-
fected with 0.1 μg per well of pRL-TK plasmid (Promega) contain-
ing the Renilla luciferase gene used for internal normalization and
various constructs containing different lengths of miR-205 promoter,
pGL3-HBx, or pGL3-Basic. The luciferase activities were measured as
previously described [21].
Western Blot Analysis
Western blot analysis was carried out as described previously [21].
The primary antibodies used were rabbit anti-E2F1 (Proteintech Group,
Chicago, IL), mouse anti-HBx (Abcam, Cambridge, United Kingdom),
and mouse anti–β-actin (Sigma-Aldrich, St Louis, MO).
Immunohistochemistry
The HCC tissue and normal liver tissue microarrays were obtained
from the Xi’an Aomei Biotechnology Co, Ltd (Xi’an, PR China),
and the primary antibody of rabbit anti-E2F1 (Proteintech Group)
was used. The sections were observed under a Carl Zeiss Axioplan
microscope (Carl Zeiss, Jena, Germany) equipped with a Leica DC500
camera (Leica, Wetzlar, Germany). Categorization of immunostaining
intensity was performed by three independent observers.
5-Aza-2′-Deoxycytidine Treatment and Methylation Analysis
The HepG2-X and HepG2.2.15 cells were treated with 5 μM
5-Aza-2′-deoxycytidine (Aza; DNA methylation inhibitor; Sigma-
Aldrich) for 72 hours, respectively. Cells were harvested, and RNA
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was extracted for qRT-PCR analysis. Genomic DNA (2 μg) of LO2,
LO2-X, HepG2, and HepG2.2.15 cells and clinical HCC tissues
(n = 2) was modified with sodium bisulfite using an EZ DNA
Methylation-Gold Kit (Zymo Research, Orange, CA). Methylation-
specific PCR (MSP) and bisulfite-sequencing analysis were then per-
formed as described previously [28]. Amplified bisulfite-sequencing
PCR products were cloned into pEASY - T1 vector (Transgen, Beijing,
PR China), and five clones from each sample were sequenced. Primer
sequences are shown in Table W1.
Analysis of Cell Proliferation
HepG2-X and HepG2.2.15 cells were seeded onto 96-well plates
(1000 cells per well) at 24 hours before transfection. Then, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-
Aldrich) and 5-ethynyl-2′-deoxyuridine (EdU; RiboBio) incorporation
assays were carried out as described previously [29]. For clonogenicity
analysis, at 48 hours after transfection, 1000 viable transfected cells
(HepG2, HepG2-X, and HepG2.2.15) were placed in six-well plates
and maintained in complete medium for 2 weeks. Colonies were
fixed with methanol and stained with methylene blue.
Animal Transplantation
Nude mice were housed and treated according to guidelines estab-
lished by the National Institutes of Health Guide for the Care and Use
of Laboratory Animals. We conducted the animal transplantation
according to the Declaration of Helsinki. Tumor transplantation in
nude mice was performed as described previously [30,31]. Briefly,
HepG2.2.15 (or HepG2) cells were harvested and resuspended
at 1 × 106 per ml with sterile phosphate-buffered saline. Groups
of 4-week-old female BALB/c athymic nude mice [Experiment Ani-
mal Center of Peking (Beijing, PR China); each group, n = 6 for
HepG2.2.15, n = 5 for HepG2] were subcutaneously injected at the
shoulder with 0.2 ml of the cell suspensions. The tumor size was mea-
sured daily until the tumor reached 50 mm3. Then, 5 μg of synthetic
miR-205, HBx plasmid (pCMV-X), HBx siRNA, or NC diluted in
Lipofectamine (Invitrogen) solution (100-μl total volume) was intra-
tumorally injected on days 9, 12, and 15 for a total of three injections
for each tumor. Tumor volume (V) was monitored by measuring the
length (L) and width (W) with calipers and calculated with the fol-
lowing formula: (L × W2) × 0.5. After 27 days, mice were killed,
and the tumors were excised and weighted.
Statistical Analysis
Each experiment was repeated at least three times. Statistical signifi-
cance was assessed by comparing mean values (±SD) using a Student’s
t test for independent groups and was assumed for *P < .05, **P <
.01, and ***P < .001. miR-205 expression levels in tumor tissues and
matched adjacent nontumor tissues were compared using theWilcoxon
signed rank test. The correlation between miR-205 (or E2F1) and
HBx mRNA levels in tumorous tissues was determined with Pearson r.
Results
HBx Is Able to Decrease miR-205 Expression in Hepatoma
and Liver Cells
It has been reported that the expression levels of miR-205 are re-
duced in several cancers, such as melanoma and prostate and breast
cancers [17,19,32]. However, it has been unclear whether miR-205
is associated with HCC. Thus, we are interested in the role of miR-
205 in liver cancer. We assessed the miR-205 expression in 33 paired
HCC and adjacent nontumorous liver tissues by qRT-PCR and
normalized against an endogenous control (U6 RNA). Interestingly,
our data indicated that the expression levels of miR-205 were reduced
in clinical HBV-related HCC samples relative to their adjacent non-
cancerous hepatic tissues (Figure 1A; P < .01, Wilcoxon signed rank
test). Next, we examined the relationships between HBx and miR-205
in HCC tissues by qRT-PCR. Intriguingly, we found that the expres-
sion levels of miR-205 were inversely correlated with those of HBx
mRNA/pregenomic RNA (pgRNA; Figure 1B; Pearson r = −0.551,
P < .001). It has been reported that the HBx sequence partially over-
lapped with the core sequence and completely overlapped with the
pgRNA [33]. On the basis of the primer sequence, the primers would
not amplify the region of core protein. It was possible that along
with HBx mRNA, the primers would amplify pgRNA. Therefore, the
qRT-PCR products should represent the amplified products from HBx
mRNA and pgRNA. Accordingly, we proposed that HBx might
downregulate miR-205 in the cells. Then, we displayed that HBx was
able to decrease miR-205 expression by transient transfection of HBx
plasmid (pCMV-X) inHepG2 or LO2 cells in a dose-dependent manner
(Figure 1C ). Strikingly, we observed that the knockdown of HBx by
pSi-HBx resulted in the increase of miR-205 levels in HepG2-X,
H7402-X, orHepG2.2.15 cells in a dose-dependentmanner (Figure 1D),
suggesting that HBx may downregulate miR-205 in the cells. The effi-
ciency of HBx overexpression (or silencing) on miR-205 in above experi-
ments was confirmed by Western blot analysis (Figure W1, A and B).
Meanwhile, the transient transfection of full-length HBV plasmid
pCH-9/3091 led to the down-regulation of miR-205 in HepG2
or LO2 cells (Figure 1E ). To further validate the effect of HBx on
miR-205, we examined whether HBx affected the expression of E2F1,
a target gene of miR-205 [17], in hepatoma and liver cells. We
found that the mRNA levels of E2F1 were positively correlated with
those of HBx/pgRNA by qRT-PCR in 33 paired HCC tissues (Fig-
ure 1F ; Pearson r = 0.566, P < .001). To demonstrate that E2F1 was
upregulated in HCC tissues, we further determined the expression
of E2F1 by immunohistochemistry in 110 clinical HCC tissues and
10 normal liver tissues. Our data revealed that 78.2% (86 of 110) of
the HCC tissues exhibited strong nuclear E2F1 immunoreactivity.
However, only 2 of 10 normal tissues displayed weak cytoplasmic and/
or nuclear E2F1 immunoreactivity (Figure W1C). Furthermore, over-
expression (or knockdown) of HBx resulted in the up-regulation (or
down-regulation) of E2F1 in the cells (Figure W1D). Thus, we con-
clude that HBx is able to downregulate expression of miR-205 in
hepatoma cells.
Russo’s group has reported that miR-125a-5p is able to interact
with HBV surface antigen and inhibits its expression [34]. In the pres-
ent study, we are interested in whether miR-205 directly targets HBx
mRNA. Then, the computational prediction was performed with
miRanda (http://www.microrna.org, Memorial Sloan-Kettering Can-
cer Center, New York, NY) by scanning the genomes of HBV subtypes
(ayw, adw, and adr) for probable target sites of the human miRNAs. As
shown in Figure 2A, there was an miR-205-binding site in the frag-
ment of HBx gene. Then, the predicted target site (or mutant target
site) sequence of miR-205 was cloned into the downstream of pGL3-
Control luciferase reporter gene vector (termed pGL3-HBx or pGL3-
HBx-mut), respectively. When the pGL3-HBx (or pGL3-HBx-mut
vector) was cotransfected with miR-205 mimics, the luciferase ac-
tivities of pGL3-HBx vector were significantly decreased compared
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with those of pGL3-HBx-mut vector in a dose-dependent manner
(Figure 2B). However, when the pGL3-HBx (or pGL3-HBx-mut
vector) was cotransfected with miR-205 inhibitors (anti–miR-205),
the luciferase activities of pGL3-HBx vector were elevated compared
with those of pGL3-HBx-mut vector in a dose-dependent manner
(Figure 2C ). Ectopic expression of miR-205 was able to markedly
repress the expression of HBx in HepG2-X and HepG2.2.15 cells at
the levels of mRNA and protein (Figure 2D). Conversely, miR-205 in-
hibitors were able to increase the HBx expression at the levels of mRNA
and protein (Figure 2E). Therefore, we conclude that miR-205 is able
to directly target HBx mRNA in the cells.
HBx Reduces miR-205 Expression through Inducing DNA
Hypermethylation of miR-205 Promoter
Next, we tried to dissect the mechanism by which HBx reduced
miR-205 expression. We first identified the miR-205 promoter core
region. Various lengths of miR-205 5′-flanking regions, including
−4178/−2751 (pGL3-1428), −3429/−2751 (pGL3-679), −4178/
−3416 (pGL3-763), −3888/−3416 (pGL3-473), and −3888/−3588
(pGL3-301), were cloned and transiently transfected into the HepG2
(or hepatoma H7402) cells to determine the promoter activities, re-
spectively. The luciferase reporter gene assays indicated that the maxi-
mum luciferase activity was exhibited by the pGL3-1428 plasmid.
The pGL3-301 plasmid exhibited the maximum activity among the
truncated plasmids (Figure 3A), indicating that the region of −3888/
−3588 is the promoter core region of miR-205. It has been reported
that the epigenetic mechanisms, such as DNA methylation and histone
modifications, can regulate the expression of miRNAs [16]. Several
miRNAs were epigenetically silenced in association with CpG island
hypermethylation in many cancers [15,29]. Therefore, the miR-205
promoter region was analyzed using CpG Island Searcher (http://
www.ualberta.ca/~stothard/javascript/cpg_islands.html, University of
Alberta, Edmonton, Canada), and bisulfite-sequencing PCR and MSP
Figure 1. HBx is able to decrease miR-205 in hepatoma and liver cells. (A) miR-205 expression was quantified by qRT-PCR in HCC and
peritumor tissues. (B) The correlation of HBx and miR-205 was determined by qRT-PCR in abovementioned HCC tissues. (C) miR-205
expression was examined by qRT-PCR in HepG2 hepatoma cells/LO2 human immortalized liver cells after transfection with pCMV-X
(HBx plasmid). (D) miR-205 expression was detected by qRT-PCR after knockdown of HBx (pSi-HBx) in hepatoma cells. (E) miR-205 expres-
sion was examined by qRT-PCR in HepG2/LO2 cells after transfection with pCH-9/3091 (HBV plasmid). (F) The correlation of HBx and E2F1
was determined by qRT-PCR in clinical HCC tissues. Data are presented asmeans± SD (*P< .05; **P< .01). We performed three separate
experiments in triplicate.
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Figure 2. miR-205 directly targets HBx mRNA. (A) The predicted binding sites for miR-205 in HBx mRNA by computational methods were
shown. Mutations were designed in the binding sites. (B and C) The plasmid pGL3-HBx or pGL3-HBx-mut was cotransfected with synthetic
miRNA mimics (miR-205) or antagomirs (anti–miR-205) into HepG2 cells. The luciferase activities of pGL3-HBx or pGL3-HBx-mut were
determined at 48 hours after transfection. (D and E) The expression of HBx was examined by qRT-PCR and immunoblot analysis, respec-
tively, after treatment with miR-205 or anti–miR-205 in the cells. Data are presented as means ± SD (*P < .05; **P < .01). We performed
three separate experiments in triplicate.
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primers were designed within the identified CpG island region using the
Methyl Primer Express Software version 1.0 (Life Technologies, Grand
Island, NY). We noted that a typical CpG island was identified from
−3825 to −3625 within the promoter region of miR-205. Then, we ex-
amined the DNAmethylation pattern in the CpG island region of miR-
205promoter by bisulfite-sequencing PCRandMSP.The results showed
that CpG sites were highly methylated in LO2-X and HepG2.2.15
cells (or two clinical HCC tissues) relative to LO2 and HepG2 cells (or
nontumorous liver tissues; Figure 3, B and C). To detect whether HBx
led to DNA hypermethylation of miR-205, we carried out qRT-PCR to
assess the expression levels of miR-205 inHepG2-X or HepG2.2.15 cells
treated with 5 μM Aza (DNA methylation inhibitor) for 72 hours. As
shown in Figure 3D, miR-205 was silenced before the treatment, but
it was dramatically activated by Aza treatment. Thus, we conclude that
HBx downregulates miR-205 through inducing DNA hypermethylation
of miR-205 promoter in hepatoma cells.
Figure 3. HBx downregulates miR-205 through inducing DNA hypermethylation of miR-205 promoter. (A) miR-205 promoter core region
was identified in hepatoma cells by luciferase reporter gene assays. (B) The methylation of miR-205 CpG sites was analyzed by bisulfite-
sequencing analysis in the cells, paired nontumor liver tissues (N), and HCC tissues (T). At least five independent clones were sequenced
per sample. Open and filled circles represent nonmethylated and methylated CpG sites, respectively. (C) The methylation of miR-205
CpG sites was examined by MSP analysis as well. (D) miR-205 expression was measured by qRT-PCR, followed by MSP analysis in the
miR-205 CpG sites in hepatoma cells treated with 5 μM Aza for 72 hours. Data are presented as means ± SD (**P < .01). We performed
three separate experiments in triplicate.
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miR-205 Is Able to Inhibit the HBx-Enhanced Proliferation
of Hepatoma Cells In Vitro
Next, we are interested in the role of miR-205 in hepatocarcino-
genesis mediated by HBx. We examined the effect of miR-205 on the
proliferation of HBx-expressing hepatoma cells by MTT and EdU
assays, respectively. Our data indicated that the overexpression of
miR-205 significantly decreased the proliferation of HepG2-X (or
HepG2.2.15) cells (Figure 4, A and B). Moreover, colony formation
assay showed that the overexpression of miR-205 resulted in the
decrease of colony numbers of HepG2-X (HepG2.2.15 or HepG2)
cells (Figures 4C and W2A), suggesting that miR-205 is able to inhibit
the proliferation of hepatoma cells in vitro.
miR-205 Is Able to Suppress the HBx-Enhanced
Proliferation of Hepatoma Cells In Vivo
Furthermore, we observed that the ectopic miR-205 expression was
able to strongly inhibit the proliferation of hepatoma cells (HepG2
and HepG2.2.15) in animal. Our data showed that miR-205 injection
into the tumors on days 9, 12, and 15 led to a significant reduction
in the size of tumor volume (Figure 5A). The average weight of tumor
intratumorally injected with synthetic miR-205 mimics was signifi-
cantly lower than that of the control injected with NC miRNA (Fig-
ures 5, B and C , and W2B), supporting that miR-205 is a tumor
suppressor miRNA. Surprisingly, we observed that the treatment with
both miR-205 and HBx was able to increase the tumor volume and
average weight in mice (Figure 5, A and B). Meanwhile, the expres-
sion levels of HBx in the tumor tissues from mice were detected by
immunoblot analysis, which was consistent with the different treat-
ments (Figure 5D). On the basis of our findings, we conclude that
miR-205 is a tumor suppressor miRNA in hepatoma cells.
HBx Promotes the Growth of Tumor through
Suppressing miR-205
Our group previously reported that HBx was able to enhance the
proliferation of hepatoma cells in mice [21]. Next, we tested the role
of miR-205 in HBx-enhanced proliferation in vivo. Interestingly, our
data revealed that the expression levels of miR-205 were decreased in
6- and 12-month-old HBx-transgenic mice relative to the wild-type
mice (Figure 6A), which was consistent with the data that the expres-
sion levels of miR-205 were inversely correlated with those of HBx
Figure 4. miR-205 inhibits the proliferation of hepatoma cells in vitro. (A–C) MTT assay, EdU incorporation assay, and clonogenicity
analysis were carried out in the cells with transfection of 100 nM miR-205, respectively. Data are presented as means ± SD (**P < .01).
We performed three separate experiments in triplicate.
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in abovementioned clinical HCC tissues. Then, we found that the
silencing of HBx resulted in the suppression of tumor growth in mice
(Figure 6, B–D). As control, we found that HBx siRNA was not able
to affect the growth of HepG2 cells in mice (Figure W3, A and B),
suggesting that HBx siRNA has no toxicity to the cells. The efficiency
of HBx RNA interference (RNAi) was shown by immunoblot analysis
(Figure 6E ). Interestingly, qRT-PCR confirmed that the expression
levels of miR-205 were increased in HBx RNAi–treated tumor tissues
from the mice transplanted with HepG2.2.15 cells (Figure 6F ), sug-
gesting that HBx RNAi releases the suppression of miR-205 mediated
by HBx in the cells. In conclusion, HBx enhances the growth of
hepatoma cells through suppressing miR-205.
Discussion
It has been reported that HBx plays an important role in regulating
transcription, signal transduction, cell cycle progress, protein deg-
radation pathway, apoptosis, and genetic stability by interaction with
various transcription factors or components of signal transduction
pathways in the development of hepatoma [35–37]. In addition, the
dysregulation of miRNAs has been found in various types of human
cancers including liver cancer [38–40]. However, whether HBx
enhances hepatocarcinogenesis through modulation of miRNAs is
poorly understood.
Growing evidence shows that the expression levels of miR-205 are
downregulated in some cancers [17,18,41]. Accordingly, we pro-
posed that the levels of miR-205 might be decreased in HCC as
well. Interestingly, as expected, we observed that miR-205 expression
levels were significantly decreased in 33 clinical HBV-related HCC
samples compared with their adjacent noncancerous hepatic tissues.
Meanwhile, we revealed that the expression levels of miR-205 were
remarkably inversed to those of HBx in HCC tissues. Due to HBx
sequence partially overlapped with the core sequence and completely
overlapped with the pgRNA, the PCR products may contain pgRNA
in Figure 1B. However, our data demonstrated that HBx was able
to depress miR-205 and miR-205 may target HBx mRNA in the
study of cell system (Figures 1 and 2), supporting that miRNA-205
is negatively associated with HBx. This finding suggests that HBx
may be involved in the down-regulation of miR-205 in HCC tissues.
Strikingly, we showed that the HBx was able to reduce miR-205 ex-
pression in hepatoma and liver cells. Therefore, we conclude that
HBx is able to inhibit miR-205 in hepatoma and liver cells. Then,
we observed that HBx was a potential target of miR-205 by target-
prediction software, which was consistent with previous prediction
by Wu et al. [42]. However, Wu et al. did not provide any experi-
mental evidence to support this prediction. In this study, our data
validated that miR-205 directly targeted HBx mRNA by experiment.
Figure 5. miR-205 inhibits the proliferation of hepatoma cells in vivo. (A) The nude mice (n = 6) were transplanted by HepG2.2.15 cells.
The tumors were injected with 5 μg (100-μl total volume) of miRNA NC, miR-205, or miR-205/HBx plasmid (pCMV-X) on days 9, 12, and
15, respectively. The growth curves of the tumors in nude mice were shown. (B) The diagram showed the average weight of tumors.
(C) The photos of tumors from mice transplanted with HepG2.2.15 cells were shown. (D) The expression levels of HBx were examined
by Western blot analysis in the tumor tissues from mice. Data are presented as means ± SD (**P < .01). We performed three separate
experiments in triplicate.
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Moreover, we showed that miR-205 was able to inhibit the expression
of HBx at the levels of mRNA and protein in hepatoma cells.
Accordingly, we puzzled over why miR-205 could not disrupt HBx
in the development of HCC. We analyzed that the suppression of
miR-205 by HBx should overcome the inhibition of HBx by miR-
205 in the event. This intrigued us to further explore the mechanism
by which HBx suppressed miR-205 in the cells. It has been reported
that the expressions of miRNAs can be modulated by the epigenetic
mechanisms, such as DNA methylation and histone modifications
[16]. Then, we analyzed the promoter regions of miR-205 and identified
a CpG island region within the promoter. We found that HBx was able
to reduce miR-205 expression through inducing hypermethylation of
miR-205 promoter. In function, it was observed that the expression
levels of miR-205 were decreased in the liver tissues of HBx-transgenic
mice (6 and 12 months old). Thus, it strongly supports that HBx en-
hances the hepatocarcinogenesis through suppressing miR-205. Indeed,
we demonstrated that HBx contributed to the proliferation of hepatoma
cells through inhibiting miR-205 in vivo. Therefore, we conclude that
miR-205 is a tumor suppressor in hepatoma cells.
Taken together, we conclude that miR-205 acts as a tumor sup-
pressor in HCC tissues. HBx is able to suppress miR-205 through
inducing hypermethylation of miR-205 promoter. Importantly, HBx
abrogates the tumor-suppressive effect of miR-205 during their inter-
action, resulting in the enhancement of hepatoma cell growth. Our
finding provides new insights into the mechanism of HBx-induced
hepatocarcinogenesis. Therapeutically, HBx may serve as a target in
HBV-related HCC.
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Figure 6. HBx promotes the growth of tumor through suppressing miR-205 in vivo. (A) miR-205 expression was examined by qRT-PCR in
6-and 12-month-old HBx-transgenic mice. (B) The nude mice (n = 6) were transplanted by HepG2.2.15 cells. The tumors were injected
with siRNA control (NC) and HBx siRNA (5 μg/100 μl) on days 9, 12, and 15, respectively. The growth curves of the tumors in nude mice
were shown. (C) The diagram showed the average weight of tumors. (D) The photos of tumors from mice were shown. (E and F) The
expression levels of HBx and miR-205 were examined by Western blot analysis and qRT-PCR in the tumor tissues from mice, respectively.
Data are presented as means ± SD (**P < .01). We performed three separate experiments in triplicate.
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Table W1. List of Primers Used in This Paper.
Gene Primer Sequence (5′-3′)































Bisulfite-sequencing analysis Forward TTAAATGTTAGGATAAGTTTTTGGTTG
Reverse AACCTTACACCTAAAACCTTAATCCT
siRNA duplexes
HBx siRNA Sense AAGAGGACUCUUGGACUCUCAdTdT
Antisense UGAGAGUCCAAGAGUCCUCUUdTdT
control siRNA Sense UUCUCCGAACGUGUCACGUdTdT
Antisense ACGUGACACGUUCGGAGAAdTdT
Figure W1. HBx is able to upregulate E2F1 in hepatoma and liver cells. (A and B) The expression levels of HBx were examined in the cells by
Western blot analysis after transfection with pCMV-X (or pSi-HBx). (C) The expression of E2F1 was examined by immunohistochemistry in
normal human liver (left) and clinical HCC (right) tissues. (D) The expression of E2F1 was examined in the cells by qRT-PCR andWestern blot
analysis after transfection with HBx (or pSi-HBx). We performed three separate experiments in triplicate.
Figure W3. The treatment with HBx siRNA does not affect the pro-
liferation of HepG2 hepatoma cells in vivo. (A) The nude mice (n =
5) were transplanted with HepG2 cells. The tumors were injected
with siRNA NC or HBx siRNA on days 9, 12, and 15, respectively.
The diagram showed the average weight of tumors. (B) The photos
of tumors from mice transplanted with HepG2 cells were shown.
Figure W2. miR-205 inhibits the proliferation of hepatoma cells
in vitro and in vivo. (A) The clonogenicity analysis was carried out
in HepG2 cells transfected with miR-205 (100 nM). (B) The nude
mice (n = 5) were transplanted with HepG2 cells. The tumors were
injected with miRNA NC or miR-205 on days 9, 12, and 15, respec-
tively. The average weight and photos of tumors were shown. Data
are presented as means ± SD (**P < .01).
